At a glance
- Originator Ipsen
- Class Antineoplastics
- Mechanism of Action Immunosuppressants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 14 Dec 2001 Discontinued-Preclinical for Cancer in France (Unknown route)
- 12 Feb 2001 Profile reviewed but no significant changes made
- 23 Oct 1997 No-Development-Reported for Cancer in France (Unknown route)